KALA Research | Milton Maxwell

KALA

KALA BIO, Inc.

0.5556

-0.0506-8.35%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

5.96M

P/E (TTM)

Basic EPS (TTM)

-5.64

Dividend Yield

Recent Filings

8-K

KALA licenses exclusive biotech AI platform

3/4/26Mar 4, 2026

KALA BIO inked a 12-month exclusive worldwide license for Younet AI's Researgency biomedical AI platform on March 3, 2026, paying $80,000 cash upfront plus 5M common shares, with optional $450,000 development fee and renewal terms at $250,000 cash + 5M shares each. The on-premises tool targets KALA's MSC-S and KPI-012 data first, enabling biotech sublicensing while data stays secure. Includes $55M option to buy Younet. Shares restricted with 3% daily volume cap.

8-K

Director Lazar resigns

2/20/26Feb 20, 2026

KALA BIO director David Lazar resigned from the board effective February 16, 2026, with no disagreements on operations, policies, or practices. The departure shrinks the board amid the biotech's challenges. No replacement named yet.

8-K

CEO/CFO resigns; Minkowitz appointed

2/5/26Feb 5, 2026

KALA BIO's David Lazar resigned as CEO and CFO on February 2, 2026, but stayed on the board. Director Avi Minkowitz stepped in immediately, bringing real estate M&A savvy from Parkit Enterprise and Leonite Capital, plus exits of two firms. Dual-role leadership persists. No related-party ties disclosed.

8-K

Closed $4.2M placement, board takeover

2/2/26Feb 2, 2026

KALA BIO closed its private placement's second tranche on January 30, 2026, issuing 2.1M shares of Series AAA Preferred Stock at $2.00 each for $4.2M gross proceeds, convertible into 882M common shares. Six directors resigned post-annual meeting approvals of issuance and 1.5B authorized share increase; AK Holdings nominated five new directors, including Avi Minkowitz, reshaping the board and committees. New investors now control the company.

8-K

Nasdaq bid price deficiency

1/23/26Jan 23, 2026

KALA Bio received a Nasdaq delisting warning on January 20, 2026, after its stock's closing bid price fell below $1.00 for 30 straight business days from December 3, 2025, to January 16, 2026. It has 180 days until July 20 to sustain $1.00 closes for 10 consecutive days. Trading continues uninterrupted. No assurance of extended cure period.

About

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

CEO

Dr. R. Kim Brazzell Ph.D.

IPO

7/20/2017

Website

https://www.kalarx.com

Employees

Sector

Healthcare

Industry

Biotechnology